newsfilter
← Latest News
GlobeNewswire·

Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development

CUE
  • Cue Biopharma appointed Dominic Borie, M.D., Ph.D. as Chief Medical Officer & Head of Research & Development.
  • Dr. Borie reports to President & CEO Shao-Lee Lin, M.D., Ph.D.
  • The company expects Phase 2 data readout for the CUE-221 program by the end of Q3 2026.
  • Cue plans to initiate Phase 1 clinical trials for CUE-401 by the end of Q4 2026.
  • The firm recently announced a $50M private placement to fund clinical development.
  • Dr. Borie brings over two decades of experience from roles at Kyverna Therapeutics, Horizon Therapeutics, Genentech, Amgen, & Roche.
  • He previously served as Director of the Transplantation Immunology Laboratory at Stanford University & practiced as a transplant surgeon in Paris.
  • The Board approved inducement equity awards consisting of 63,000 stock options & 31,500 restricted stock units for Dr. Borie.
  • The equity awards vest over four years subject to continued employment.
  • Cue Biopharma remains focused on advancing therapies for immune-mediated diseases using its Immuno-STAT® platform.